Clinical trials: BIA
Healthy
Generation of Normal Ranges to Analyze Body Composition of Adults Based on Bioelectrical Impedance Analysis (BIA)
The aim of the study is to generate normal ranges for φ, BIVA and BCC. The calculation of FMI and FFMI is based on the results of two other clinical investigations: "Generation of prediction equation to analyze body composition…
- Trial name
- NCT01481285
- Where
- Germany
- Volunteers
- 992 people, healthy volunteers welcome
- Sponsor
- Seca GmbH & Co. Kg.
Skin Aging, Skin Hydration
Skin Hydration and Facial Aging in Women Aged 30-60: An Observational Correlational Study Using Bioimpedance Analysis
This study investigates whether skin hydration levels are related to how old the skin looks. Thirty women aged 30 to 60 years will attend a single visit at a licensed esthetic practice in Florida.
- Conditions
- Skin Aging, Skin Hydration, Facial Aging, Transepidermal Water Loss
- Trial name
- SHFA-30-60 (NCT07564869)
- Testing
- BT-Analyze Bioimpedance Measurement
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- IAS Skin Care
Parkinson Disease
A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects
The purpose of this study was to investigate the safety, tolerability, pharmacokinetics and catechol-O-methyltransferase (COMT) activity of BIA 9-1067 in healthy male subjects after single oral ascending doses.
- Trial name
- NCT01520727
- Testing
- BIA 9-1067
- Where
- France
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg
The purpose of this study was to determine whether the administration of BIA 6-512 (25 mg, 50 mg, 75 mg and 100 mg) at steady-state affects the pharmacokinetics of levodopa when administered in combination with a single-dose of…
- Trial name
- NCT03097211
- Testing
- BIA 6-512, Madopar® 250, Nebicapone
- Where
- Portugal
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pulmonary Arterial Hypertension
Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058
the purpose of this study is to determine the effect of age on the Pharmacokinetics (PK) profile of BIA 5-1058 at steady state after multiple oral doses
- Trial name
- NCT04991194
- Testing
- BIA 5-1058
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects
the purpose of the study was to the compare pharmacokinetic profile of BIA 6-512 in healthy elderly subjects versus healthy young subjects after single and repeated oral administration of 200 mg BIA 6-512.
- Trial name
- NCT03095105
- Testing
- 200 mg BIA 6-512
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Epilepsy
A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093
The purpose of this study is to investigate the safety and tolerability of multiple dose regimens of BIA 2-093 in healthy young male volunteers
- Trial name
- NCT02171234
- Testing
- BIA 2-093
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Bioelectrical Impedance Measurement of Healthy Adults
Generation of Prediction Equations to Analyze Body Composition of Adults Based on Bioelectrical Impedance Analysis (BIA)
Aim of the study is to develop prediction equations for calculating FFM, TBW, ECW and SMM based on the gold standard reference methods ADP, DXA, MRI, D2O and NaBr on the one hand and measurement data of the BIA devices on the…
- Trial name
- NCT01368640
- Where
- Germany
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Seca GmbH & Co. Kg.
Partial Epilepsy
Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive
The purpose of this study is to investigate whether multiple-dose administration of eslicarbazepine acetate (ESL, BIA 2-093) 800 mg once-daily (QD) affects the pharmacokinetics and tolerability of the components of a combined…
- Trial name
- NCT00898560
- Testing
- eslicarbazepine acetate and Microginon®, Microginon®
- Where
- Portugal
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites
To determine the absorption, metabolism and excretion of BIA 9-1067.
- Trial name
- NCT01515891
- Testing
- BIA 9-1067
- Where
- Switzerland
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Epilepsy
Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites
The purpose of this study is to determine the effects of age on the pharmacokinetic profile of BIA 2-093 and its active metabolites.
- Trial name
- NCT02172755
- Testing
- BIA 2-093
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pulmonary Arterial Hypertension
Absorption, Distribution, Metabolism and Excretion of BIA 5-1058
the purpose of this study is: to determine the rate and routes of excretion of BIA 5-1058 and the mass balance in urine, feces and exhaled air, after a single oral dose of 400 mg 14C labeled BIA 5 1058 containing 3.7…
- Trial name
- ADME (NCT04991181)
- Testing
- 400 mg BIA 5-1058
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic
To investigate the effect of repeated dosing of BIA 9-1067 on the levodopa pharmacokinetics, in comparison to placebo and entacapone.
- Trial name
- NCT01519284
- Testing
- BIA 9-1067 5 mg, Entacapone, levodopa/carbidopa
- Where
- Portugal
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women
The purpose of this study is to evaluate the effect of BIA 9-1067 on the cardiac repolarization in adult healthy men and women volunteers.
- Trial name
- NCT01532115
- Testing
- BIA 9-1067, moxifloxacin
- Where
- France
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067
The purpose is to and to assess the mass balance recovery after a single oral dose of [14C]-BIA 9-1067 and to provide plasma, urine and faecal samples for metabolite profiling and structural identification.
- Trial name
- NCT03119194
- Testing
- [14C]-BIA 9-1067
- Where
- United Kingdom
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202
The objectives as stated in the study protocol were as follows: To investigate the safety and tolerability of three multiple dose regimens of BIA 3-202 (50 mg twice a day, 100 mg twice a day and 200 mg twice a day in healthy…
- Trial name
- NCT02763800
- Testing
- BIA 3-202
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Hypertension, Chronic Heart Failure
Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453
The purpose of this study is to assess the tolerability of BIA 5-453 after six multiple rising dose regimens of BIA 5-453.
- Trial name
- NCT02840565
- Testing
- BIA 5-453
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Hypertension, Chronic Heart Failure
Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453
The purpose of this study is to assess the safety and tolerability of BIA 5-453 after single oral doses
- Trial name
- NCT02845037
- Testing
- BIA 5-453
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156
The study is designed to determine the absorption, distribution, metabolism and elimination (ADME) of BIA 28-6156 in humans, further explore the PK of BIA 28-6156, evaluate the extent of distribution of total radioactivity into…
- Trial name
- NCT05220072
- Testing
- Carbon-14 BIA 28-6156
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bial R&D Investments, S.A.
Hypertension, Congestive Heart Failure
Bioavailability Study of BIA 5-453
The purpose of this study was to compare the bioavailability and tolerability of BIA 5-453 under fasted and fed conditions.
- Trial name
- NCT03090568
- Testing
- BIA 5-453
- Where
- France
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.